ESMO 2022 | Targeting EGFR for the treatment of inflammatory breast cancer

Naoto Ueno, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the development of novel therapies to improve outcomes for patients with inflammatory breast cancer. Inflammatory breast cancer represents 2-4% of breast cancer cases and 10% of breast cancer mortalities. Over the last three decades, there has been no improvement in overall-survival (OS). Dr Ueno suggests targeting EGFR for the treatment of inflammatory breast cancer may provide the means to improve patient outcomes due to the resulting tumor microenvironment (TME) modulation. Historically, pathological complete response (pCR) rates have been 12-15% when treating inflammatory breast cancer, however, a Phase II study exploring panitumumab combined with chemotherapy observed a pCR rate of almost 42%, providing a rationale for further investigation. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.